Comprehensive Stock Comparison
Compare YD Bio Limited Ordinary Shares (YDES) vs Veracyte, Inc. (VCYT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  YDES | 45.8% revenue growth vs VCYT's 16.0% |
| Quality / Margins |  VCYT | 12.8% net margin vs YDES's -276.6% |
| Stability / Safety | VCYT | Beta 1.12 vs YDES's 1.64 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | VCYT | +0.9% vs YDES's -27.7% |
| Efficiency (ROA) | VCYT | 4.7% ROA vs YDES's -100.8%, ROIC 4.4% vs -63.3% |
Who Each Stock Is For
Income & stability
VCYTbeta 1.12
Growth exposure
YDESRev growth 45.8%
Long-term compounding (10Y)
VCYT431.1% 10Y total return vs YDES's -27.7%
Sleep-well-at-night portfolio
YDESLower volatility, beta 1.64, Low D/E 0.3%, current ratio 13.18x
Defensive / Recession hedge
VCYTBeta 1.12, current ratio 8.15x
Business Model
What each company does and how it makes money
YD Bio is a clinical-stage biopharmaceutical company developing exosome-based therapeutics for cancer prevention and treatment. It generates revenue primarily through research grants and partnerships — with future income expected from drug licensing and commercialization — though it's currently in pre-revenue stages as it advances its pipeline. The company's competitive advantage lies in its proprietary exosome technology platform, which targets diseases with significant unmet medical needs.
Veracyte is a molecular diagnostics company that develops genomic tests to improve cancer and other disease diagnosis and treatment decisions. It generates revenue primarily from diagnostic test sales — including its Afirma thyroid, Decipher prostate, and Percepta lung cancer tests — with additional income from technology licensing partnerships. The company's competitive advantage lies in its proprietary genomic classifiers and biobank of clinical samples that enable development of clinically validated tests with strong physician adoption.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VCYT 5YDES 0VCYT5/5 metricsVCYT2/3 metricsVCYT6/8 metricsVCYT6/6 metricsVCYT2/2 metricsVCYT leads in 5 of 6 categories — strongest in Financial Metrics and Valuation Metrics.
Financial Metrics (TTM)
VCYT and YDES operate at a comparable scale, with $517M and $0 in trailing revenue. VCYT is the more profitable business, keeping 12.8% of every revenue dollar as net income compared to YDES's -2.8%.
| Metric | YDESYD Bio Limited Or… | VCYTVeracyte, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $517M |
| EBITDAEarnings before interest/tax | -$3M | $74M |
| Net IncomeAfter-tax profit | -$3M | $66M |
| Free Cash FlowCash after capex | -$1M | $126M |
| Gross MarginGross profit ÷ Revenue | +30.4% | +70.1% |
| Operating MarginEBIT ÷ Revenue | -2.9% | +11.2% |
| Net MarginNet income ÷ Revenue | -2.8% | +12.8% |
| FCF MarginFCF ÷ Revenue | -9.3% | +24.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +18.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -116.0% | +7.3% |
Valuation Metrics
| Metric | YDESYD Bio Limited Or… | VCYTVeracyte, Inc. |
|---|---|---|
| Market CapShares × price | $614M | $2.7B |
| Enterprise ValueMkt cap + debt − cash | $610M | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -15.54x | 41.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 20.90x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 41.68x |
| Price / SalesMarket cap ÷ Revenue | 1202.16x | 5.28x |
| Price / BookPrice ÷ Book value/share | 5.47x | 2.12x |
| Price / FCFMarket cap ÷ FCF | — | 21.57x |
Profitability & Efficiency
VCYT delivers a 5.1% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-43 for YDES. YDES carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to VCYT's 0.03x. On the Piotroski fundamental quality scale (0–9), VCYT scores 8/9 vs YDES's 3/9, reflecting strong financial health.
| Metric | YDESYD Bio Limited Or… | VCYTVeracyte, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -42.7% | +5.1% |
| ROA (TTM)Return on assets | -100.8% | +4.7% |
| ROICReturn on invested capital | -63.3% | +4.4% |
| ROCEReturn on capital employed | -44.1% | +4.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 8 |
| Debt / EquityFinancial leverage | 0.00x | 0.03x |
| Net DebtTotal debt minus cash | -$3M | -$323M |
| Cash & Equiv.Liquid assets | $3M | $363M |
| Total DebtShort + long-term debt | $22,555 | $40M |
| Interest CoverageEBIT ÷ Interest expense | -1893.69x | — |
Total Returns (with DRIP)
A $10,000 investment in VCYT five years ago would be worth $7,336 today (with dividends reinvested), compared to $7,226 for YDES. Over the past 12 months, VCYT leads with a +0.9% total return vs YDES's -27.7%. The 3-year compound annual growth rate (CAGR) favors VCYT at 13.2% vs YDES's -10.3% — a key indicator of consistent wealth creation.
| Metric | YDESYD Bio Limited Or… | VCYTVeracyte, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -27.5% | -18.8% |
| 1-Year ReturnPast 12 months | -27.7% | +0.9% |
| 3-Year ReturnCumulative with dividends | -27.7% | +45.0% |
| 5-Year ReturnCumulative with dividends | -27.7% | -26.6% |
| 10-Year ReturnCumulative with dividends | -27.7% | +431.1% |
| CAGR (3Y)Annualised 3-year return | -10.3% | +13.2% |
Risk & Volatility
VCYT is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than YDES's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VCYT currently trades 67.9% from its 52-week high vs YDES's 34.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | YDESYD Bio Limited Or… | VCYTVeracyte, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.64x | 1.12x |
| 52-Week HighHighest price in past year | $25.00 | $50.71 |
| 52-Week LowLowest price in past year | $5.30 | $22.61 |
| % of 52W HighCurrent price vs 52-week peak | +34.8% | +67.9% |
| RSI (14)Momentum oscillator 0–100 | 36.8 | 45.5 |
| Avg Volume (50D)Average daily shares traded | 39K | 651K |
Analyst Outlook
| Metric | YDESYD Bio Limited Or… | VCYTVeracyte, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $47.25 |
| # AnalystsCovering analysts | — | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| YD Bio Limited Ordi… (YDES) | $0.00 | $510360.00 | — |
| Veracyte, Inc. (VCYT) | $65M | $517M | +694.6% |
Veracyte, Inc.'s revenue grew from $65M (2016) to $517M (2025) — a 25.9% CAGR.
Chart 2Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| YD Bio Limited Ordi… (YDES) | 3.9% | -2.8% | -171.4% |
| Veracyte, Inc. (VCYT) | -48.2% | 12.8% | +126.6% |
Veracyte, Inc.'s net margin went from -48% (2016) to 13% (2025).
Chart 3EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| YD Bio Limited Ordi… (YDES) | -0.17 | -0.56 | -229.4% |
| Veracyte, Inc. (VCYT) | -1.09 | 0.82 | +175.2% |
Veracyte, Inc.'s EPS grew from $-1.09 (2016) to $0.82 (2025).
Chart 4Free Cash Flow — 5 Years
YD Bio Limited Ordinary Shares generated $-5M FCF in 2024 (-590% vs 2021). Veracyte, Inc. generated $127M FCF in 2025 (+442% vs 2021).
YDES vs VCYT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is YDES or VCYT a better buy right now?
Veracyte, Inc. (VCYT) offers the better valuation at 42.0x trailing P/E (20.9x forward), making it the more compelling value choice. Analysts rate Veracyte, Inc. (VCYT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — YDES or VCYT?
Over the past 5 years, Veracyte, Inc. (VCYT) delivered a total return of -26.6%, compared to -27.7% for YD Bio Limited Ordinary Shares (YDES). A $10,000 investment in VCYT five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VCYT returned +431.1% versus YDES's -27.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — YDES or VCYT?
By beta (market sensitivity over 5 years), Veracyte, Inc. (VCYT) is the lower-risk stock at 1.12β versus YD Bio Limited Ordinary Shares's 1.64β — meaning YDES is approximately 46% more volatile than VCYT relative to the S&P 500. On balance sheet safety, YD Bio Limited Ordinary Shares (YDES) carries a lower debt/equity ratio of 0% versus 3% for Veracyte, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — YDES or VCYT?
Veracyte, Inc. (VCYT) is the more profitable company, earning 12.8% net margin versus -276.6% for YD Bio Limited Ordinary Shares — meaning it keeps 12.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VCYT leads at 11.2% versus -286.5% for YDES. At the gross margin level — before operating expenses — VCYT leads at 70.1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — YDES or VCYT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is YDES or VCYT better for a retirement portfolio?
For long-horizon retirement investors, Veracyte, Inc. (VCYT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.12), +431.1% 10Y return). YD Bio Limited Ordinary Shares (YDES) carries a higher beta of 1.64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VCYT: +431.1%, YDES: -27.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between YDES and VCYT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.